Neurotech International
Neurotech International is a publicly listed Australian clinical-stage biotechnology company developing therapeutic candidates for Autism Spectrum Disorder (ASD), with lead candidate suramin sodium (KZ101). The Perth-based company is pre-revenue and advancing its ASD pipeline.
- Company typePrivate
- Founded2016
- HeadquartersPerth, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neurotech International does
Neurotech International Limited is an Australian clinical-stage biotechnology company listed on the Australian Securities Exchange (ASX: NTI), headquartered in Perth and founded in 2016. The company is developing therapeutic candidates targeting Autism Spectrum Disorder (ASD), a therapeutic area with significant unmet medical need and limited approved treatment options for core ASD symptoms. Its lead candidate appears to be suramin sodium (KZ101), referenced in clinical trial context as the primary asset advancing through development.
The company's business model is presently pre-commercial: it operates in clinical development with no marketed products, no publicly disclosed pricing model, and no commercial distribution infrastructure. Revenue recognition would only become material upon regulatory approval and successful commercialization of its pipeline therapies. Neurotech employs between 11 and 50 staff and is led by CEO Wolfgang Storf, founder and non-executive director Adrian Attard Trevisan, and CCO Mario Raciti. The company's value proposition is the development of a therapeutic pipeline for ASD, an indication where over 25 companies are reportedly pursuing pipeline therapies.
In December 2025, Neurotech requested a trading halt on its listed securities pending a capital raising announcement, indicating active fundraising to advance the clinical pipeline. The company previously raised $4,000,000 in an October 2017 funding round. The provided financial figures (revenue and EBITDA reported in trillions of dollars) are internally inconsistent with a sub-50-employee clinical-stage biotech and should be treated as unreliable input; on the underlying fundamentals, the company is pre-revenue.
Neurotech International firmographics
Firmographics- Name
- Neurotech International
- Website
- https://neurotechinternational.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neurotech International is a publicly listed Australian clinical-stage biotechnology company developing therapeutic candidates for Autism Spectrum Disorder (ASD), with lead candidate suramin sodium (KZ101). The Perth-based company is pre-revenue and advancing its ASD pipeline.
- Ownership category
- akta.pro rank
Neurotech International industry classification
Industry- Product category
- Neurological Therapeutics — Autism Spectrum Disorder
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Neurotech International is headquartered
LocationHeadquarters
- HQ city
- Perth
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Neurotech International business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Neurotech International product offering
Product offeringCore offering
Neurotech International is a clinical-stage biotechnology/medical device company developing novel therapeutic candidates for central nervous system disorders, with a primary focus on autism spectrum disorder (ASD). Its lead asset is suramin sodium (KZ101), which is being advanced through clinical development as a potential treatment for ASD.
Product overview
No product or service information is available from the provided sources. The company website (neurotechinternational.com) displays only a loading/verification page, and no product details are present in the available news articles.
Differentiator
Problem solved
Functional benefit
Products and services
- Suramin sodium (KZ101) Suramin sodium (KZ101) is Neurotech International's lead proprietary therapeutic candidate in clinical development, intended to address the significant unmet medical need for pharmacological treatment options for autism spectrum disorder.
Companies that use Neurotech International
Customer profileSegments1 record
Ideal customer profiles1 record
Neurotech International technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Neurotech International partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights3 records
Neurotech International competitors and assessment
Company assessmentDirect peers
- Axsome Therapeutics: Clinical CNS-focused biotech developing therapeutics for neurological and psychiatric disorders. Comparable as a small-cap publicly listed CNS biotech that has navigated from clinical development to commercialization, offering a trajectory benchmark for Neurotech.
- Ovid Therapeutics: Clinical-stage biotech focused on rare neurological and neurodevelopmental conditions, including Angelman syndrome and Fragile X — both adjacent to ASD. Closely comparable in indication strategy, company size, and public-market funding model.
- Yamo Pharmaceuticals: Emerging clinical-stage company developing a first-in-class therapy specifically for the core symptoms of ASD. Directly comparable as an ASD-focused clinical-stage therapeutic developer with similar size and stage profile.
- Zynerba Pharmaceuticals: Clinical-stage biotech developing cannabinoid-based therapeutics for neurodevelopmental and psychiatric conditions including ASD and Fragile X syndrome. Highly comparable in target indication, modality, and small-cap clinical-stage profile.
- Sage Therapeutics: Clinical-stage CNS-focused biotech developing therapeutics for neurological and neuropsychiatric conditions. Highly comparable in stage, listing status, and CNS drug development focus, providing a useful reference for valuation, capital strategy, and pipeline prioritization.
- Curemark: Clinical-stage biotech developing CM-AT for autism spectrum disorder, one of the most direct ASD-only therapeutic competitors. Closely comparable on indication focus and clinical-stage development stage.
Broad incumbents
- Roche: Global pharmaceutical leader that has run major ASD clinical programs (e.g., balovaptan) and operates broadly in CNS/neurodevelopmental therapeutics. Comparable as a benchmark for capital intensity, trial design, and competitive positioning in ASD, even though Neurotech operates at a vastly different scale.
- BioMarin Pharmaceutical: Established rare-disease biopharmaceutical company with a CNS and neurodevelopmental franchise (e.g., Voxzogo for rare skeletal conditions; pipeline adjacent to neuro). Useful as a comparator for the orphan/specialty CNS commercial model and valuation framework.
Emerging players
- MapLight Therapeutics: Clinical-stage neuroscience company developing therapeutics for CNS disorders with partial overlap in neurodevelopmental indications. Comparable as a clinical-stage CNS peer with a similar public/private funding trajectory.
- Stalicla: Clinical-stage biotech developing precision therapeutics for neurodevelopmental disorders including ASD subgroups. Comparable as a niche ASD-focused clinical developer, useful for benchmarking the precision-medicine angle in ASD drug development.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Neurotech International social profiles
Digital presenceNeurotech International financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurotech International leadership team
Management profileNumber of profiles
Profiles3 records
Neurotech International funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurotech International M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurotech International
What does Neurotech International do?
Neurotech International is a clinical-stage biotechnology/medical device company developing novel therapeutic candidates for central nervous system disorders, with a primary focus on autism spectrum disorder (ASD). Its lead asset is suramin sodium (KZ101), which is being advanced through clinical development as a potential treatment for ASD.
When was Neurotech International founded?
Neurotech International was founded in 2016. It employs 11 to 50 people.
Where is Neurotech International based?
Neurotech International is headquartered in Perth, Australia, in the Oceania region.
Who are Neurotech International's main competitors?
Direct peers on record are Axsome Therapeutics, Ovid Therapeutics, Yamo Pharmaceuticals, Zynerba Pharmaceuticals, Sage Therapeutics and Curemark. Broad incumbents are Roche and BioMarin Pharmaceutical. Emerging players are MapLight Therapeutics and Stalicla.
Does Neurotech International have an API?
No public API is recorded for Neurotech International.
What industry is Neurotech International in?
Neurotech International's product category is Neurological Therapeutics — Autism Spectrum Disorder. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.